Contact us

2026

Tetraneuron receives European Commission Seal of Excellence for TET-101 proposal

by

Tetraneuron has received a Seal of Excellence from the European Commission for its TET-101 project proposal, submitted to the 2026 EIC Accelerator Open call under Horizon Europe. An international panel of independent experts recognised the proposal as high quality in a highly competitive evaluation. The European Commission has recommended it for funding by other sources. … Read more

Tetraneuron receives approval to initiate first-in-human clinical testing of TET-101 in Alzheimer’s disease patients in Australia

by

Australia authorises the clinical evaluation of TET-101, Tetraneuron’s E2F4DN-based gene therapy programme with the potential to slow neurodegeneration and restore cognitive functions affected by Alzheimer’s disease. Madrid, 17 June 2026 —Tetraneuron, a Spanish biotechnology company focused on the development of gene therapies for neurodegenerative diseases, announces that it has received approval to proceed with first-in-human … Read more

Contact

Online contact form

TETRANEURON S.L processes your personal data in order to be able to manage the queries you ask us. You can exercise your rights of access, rectification, deletion, opposition, portability and limitation through our email info@tetraneuron.com. For more information you can access our Privacy Policy